Biologics & Injectables Index
Convert Unblinded Payer Perceptions into Insights
- Examine Payer Reactions to Healthcare Trends: Analyze how payers respond to key healthcare topics and market developments each quarter to stay ahead of industry shifts.
- Assess Payer Management Strategies: Evaluate payer management techniques, site-of-care trends, and administrative burden via Access Management Topics.
- Review Therapeutic Area Trends and Emerging Therapies: Gain deep insights into specific therapeutic areas, including disruptive market events and payer perceptions of new and emerging therapies.
- Inform Strategy and Market Access Decisions: Access insights from leading payer stakeholders representing 75% of Commercial and Medicare lives.
Track Biologics and Injectables Trends with Confidence
What Our Clients Are Saying
"For rare diseases, traditional labs and claims data alone haven’t given us the depth we need to act. Norstella’s EMR data is changing that. The level of clarity is redefining how we go to market."
Director, Commercial and Medical IT, Rare Disease
Global Biotech Company
"For rare diseases, traditional labs and claims data alone haven’t given us the depth we need to act. Norstella’s EMR data is changing that. The level of clarity is redefining how we go to market."
Director, Commercial and Medical IT, Rare Disease
Global Biotech Company
"For rare diseases, traditional labs and claims data alone haven’t given us the depth we need to act. Norstella’s EMR data is changing that. The level of clarity is redefining how we go to market."
Director, Commercial and Medical IT, Rare Disease
Global Biotech Company
"For rare diseases, traditional labs and claims data alone haven’t given us the depth we need to act. Norstella’s EMR data is changing that. The level of clarity is redefining how we go to market."
Director, Commercial and Medical IT, Rare Disease
Global Biotech Company
How We Can Help
Harness the power of MMIT’s Biologics & Injectables Index, built on robust field research with an industry-leading panel of pharmacy decision-makers. 100% of panellists are either active P&T participants or control access for pharmaceuticals for their organizations, delivering unparalleled market access visibility and actionable payer perspectives to inform your team’s strategic choices.
The Biologics & Injectables Index helps your team understand payer perspectives and decision‑making by capturing unblinded insights from active P&T participants and access controllers across plans, PBMs, providers, and IDNs, revealing how they evaluate biologic and injectable therapies.
The Biologics & Injectables Index identifies trends in coverage, site‑of‑care dynamics, and emerging therapies by tracking quarterly payer reactions, access management topics, and therapeutic‑area shifts that highlight evolving market dynamics.
The Biologics & Injectables Index informs market access and commercial strategy by providing forward‑looking payer, HCP, and practice‑manager insights that clarify anticipated coverage changes, administration burdens, and competitive pressures across Commercial and Medicare lines of business.
Key Insights From MMIT
Access Trends for Innovative Technology Cell and Gene Therapies, Biomarkers, and Telemedicine
Access barriers to the use of innovative technology such as administrative burden and reimbursement challenges. We will also touch upon payer concern about costs which might be underlying these issues.
Solutions to Support Your Strategy
Enhance the Biologics & Injectables Index with related solutions that provide broader visibility into coverage decisions, patient journeys, and emerging therapies. This enables your team to move from insight to confident, informed action.
Message Monitor
Use Message Monitor to capture key payer and IDN decision-makers’ insights around brand perception so you can better position your product against the competition.
Oncology Index
Leverage the MMIT Oncology Index to synthesize insights into an analysis of payer trends, oncology management, and disruptive market events.
P&T Perspectives
P&T Perspectives provides qualitative and tangible feedback through a simulated P&T session that informs your brand’s strategy and helps you determine how your product—or your competitor’s product—will fare in a real P&T Committee review.
Rapid Response
Improve your brand strategy with Rapid Response’s quick, actionable answers to key business questions among a representative sample of the payer and IDN stakeholders that you care about.